Literature DB >> 16503061

The silent treatment: RNAi as a defense against virus infection in mammals.

Ronald P van Rij1, Raul Andino.   

Abstract

RNA interference (RNAi) is a mechanism for sequence-specific gene silencing guided by double-stranded RNA. In plants and insects it is well established that RNAi is instrumental in the response to viral infections; whether RNAi has a similar function in mammals is under intense investigation. Recent studies to address this question have identified some unanticipated interactions between the RNAi machinery and mammalian viruses. Furthermore, introduction of virus-specific small interfering RNAs (siRNAs) into cells, thus programming the RNAi machinery to target viruses, is an effective therapeutic approach to inhibit virus replication in vitro and in animal models. Although several issues remain to be addressed, such as delivery and viral escape, these findings hold tremendous potential for the development of RNAi-based antiviral therapeutics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16503061     DOI: 10.1016/j.tibtech.2006.02.006

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  42 in total

1.  Large-scale production of dsRNA and siRNA pools for RNA interference utilizing bacteriophage phi6 RNA-dependent RNA polymerase.

Authors:  Antti P Aalto; L Peter Sarin; Alberdina A van Dijk; Mart Saarma; Minna M Poranen; Urmas Arumäe; Dennis H Bamford
Journal:  RNA       Date:  2007-01-19       Impact factor: 4.942

2.  Virus meets RNAi. Symposium on antiviral applications of RNA interference.

Authors:  Ronald P van Rij
Journal:  EMBO Rep       Date:  2008-07-18       Impact factor: 8.807

3.  Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway.

Authors:  Giulia Fabozzi; Christopher S Nabel; Michael A Dolan; Nancy J Sullivan
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

4.  Requirement for CRIF1 in RNA interference and Dicer-2 stability.

Authors:  Su Jun Lim; Anthony Scott; Xiao-Peng Xiong; Shabnam Vahidpour; John Karijolich; Dongdong Guo; Shanshan Pei; Yi-Tao Yu; Rui Zhou; Willis X Li
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

5.  The RNA silencing endonuclease Argonaute 2 mediates specific antiviral immunity in Drosophila melanogaster.

Authors:  Ronald P van Rij; Maria-Carla Saleh; Bassam Berry; Catherine Foo; Andrew Houk; Christophe Antoniewski; Raul Andino
Journal:  Genes Dev       Date:  2006-11-01       Impact factor: 11.361

6.  Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production.

Authors:  Sandesh Subramanya; Sang-Soo Kim; Sojan Abraham; Jiahong Yao; Mukesh Kumar; Priti Kumar; Viraga Haridas; Sang-Kyung Lee; Leonard D Shultz; Dale Greiner; Manjunath N; Premlata Shankar
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

Review 7.  New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.

Authors:  Konstantin Chumakov; Ellie Ehrenfeld
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

8.  The 5'-end heterogeneity of adenovirus virus-associated RNAI contributes to the asymmetric guide strand incorporation into the RNA-induced silencing complex.

Authors:  Ning Xu; Sofia Gkountela; Khalid Saeed; Göran Akusjärvi
Journal:  Nucleic Acids Res       Date:  2009-09-15       Impact factor: 16.971

9.  Selection of potent non-toxic inhibitory sequences from a randomized HIV-1 specific lentiviral short hairpin RNA library.

Authors:  Carola Pongratz; Benjamin Yazdanpanah; Hamid Kashkar; Maik J Lehmann; Hans-Georg Kräusslich; Martin Krönke
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

Review 10.  Engineering RNA for targeted siRNA delivery and medical application.

Authors:  Peixuan Guo; Oana Coban; Nicholas M Snead; Joe Trebley; Steve Hoeprich; Songchuan Guo; Yi Shu
Journal:  Adv Drug Deliv Rev       Date:  2010-03-15       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.